Ask AI
ProCE Banner Activity

Lenacapavir Approval: What to Know When Selecting a PrEP Regimen

Podcast Episodes

Tune in to learn how the recent FDA approval of lenacapavir (LEN) for PreP integrates into the current field of HIV prevention. Listen on the go or follow along with our expert-curated slides.

Released: August 14, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with American Academy of HIV Medicine, Association of Nurses in AIDS Care (ANAC), and HealthHIV  

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

American Academy of HIV Medicine

ProCE Banner

ANAC

ProCE Banner

HealthHIV

ProCE Banner

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Explain how clinical trial data and US FDA approval of LEN for HIV PrEP fits in the HIV prevention toolbox

Disclosure

Primary Author

Colleen F. Kelley, MD, MPH: researcher: Gilead, Moderna, Novavax, ViiV.

Raphael J. Landovitz, MD, MSc: consultant/advisor: Merck, ViiV.